SLU-PP-332
Molecular Identifiers
Overview
Novel metabolic compound. ERRα/γ agonist with exercise mimetic properties. Research ongoing. Follow specific study protocols.
Small molecule — synthetic ERR (estrogen-related receptor) agonist, not a peptide
Half-life
~4-8 hours
Administration Route
Oral or subcutaneous
Category
Metabolic & Fat Loss
Mechanism of Action
- ERRα and ERRγ receptor agonism
- Activation of muscle exercise programs
- Improvement of mitochondrial oxidative capacity
- Increased type I muscle fiber gene expression
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | Variable dosage per research |
| Frequency | Per protocol |
| Timing | Per research protocol |
| Duration | Per specific study |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Gastrointestinal discomfort
- Transient fatigue
- Mild headache
Presentations & Preparation
Vials of SLU-PP-332 found in the research market:
Reconstitution
- Diluent: Per protocol
- Volume: Per protocol
- Follow specific study protocol
Storage
- Lyophilized: -20°C
- Reconstituted: Per protocol
- Compound in active research phase
Scientific Studies
Published studies on SLU-PP-332.
Synthetic ERRalpha/beta/gamma Agonist Induces an ERRalpha-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity
Billon C, Sitaula S, Banerjee S, Welch R, Elgendy B, Hegazy L, Oh TG, Kazantzis M, et al.
A Synthetic ERR Agonist Alleviates Metabolic Syndrome
Billon C, Schoepke E, Avdagic A, Chatterjee A, Butler AA, Elgendy B, Walker JK, Burris TP
Related Peptides
5-Amino-1MQ
50 mg per capsule · 1-2 times daily
Adipotide
0.5-1 mg/kg per injection (subcutaneous) · Once daily
AICAR
50-150 mg per injection · 2-3 times per week
AOD 9604
300-600 mcg per injection · Once daily
Cagrilintide
1.2-4.5 mg per week (subcutaneous) · Once weekly
Dulaglutide
0.75-4.5 mg per week (subcutaneous) · Once weekly